1. Home
  2. PMM vs LUNG Comparison

PMM vs LUNG Comparison

Compare PMM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$6.11

Market Cap

276.3M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.38

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMM
LUNG
Founded
1989
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.3M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PMM
LUNG
Price
$6.11
$1.38
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
87.0K
711.1K
Earning Date
01-01-0001
03-04-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
7.64
EPS
0.23
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$6.20
Revenue Next Year
N/A
$21.61
P/E Ratio
$26.83
N/A
Revenue Growth
N/A
8.01
52 Week Low
$5.66
$1.31
52 Week High
$6.52
$7.46

Technical Indicators

Market Signals
Indicator
PMM
LUNG
Relative Strength Index (RSI) 32.14 38.69
Support Level $6.06 N/A
Resistance Level $6.19 $1.97
Average True Range (ATR) 0.07 0.17
MACD -0.03 -0.03
Stochastic Oscillator 8.41 7.65

Price Performance

Historical Comparison
PMM
LUNG

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: